文献速递骨软组织肉瘤与黑色素瘤

DeCOG-SLT最终分析:前哨淋巴结阳性黑色素瘤患者完成淋巴结清扫无生存获益

Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.
PubMed 文献 · J Clin Oncol · 2019-09-26

德国皮肤肿瘤协作组III期随机试验最终分析,中位随访72个月,比较前哨淋巴结阳性黑色素瘤患者接受完成淋巴结清扫(CLND)与观察的结局。CLND组3-4级不良事件13%。结果不支持对前哨淋巴结转移患者常规推荐CLND。

要点

  • 前哨淋巴结阳性黑色素瘤患者立即CLND未改善无远处转移生存、无复发生存或总生存。
  • CLND组3-4级不良事件发生率为13%,以淋巴水肿和伤口延迟愈合最常见。
  • 最终分析支持不推荐前哨淋巴结转移患者常规行完成淋巴结清扫。

核心结论

  • 前哨淋巴结阳性黑色素瘤患者立即行完成淋巴结清扫在无远处转移生存、无复发生存和总生存方面不优于观察。
  • 最终分析结果支持不推荐对前哨淋巴结转移患者行完成淋巴结清扫。

研究设计与样本

  • 多中心随机III期试验(DeCOG-SLT,NCT02434107),纳入躯干和四肢皮肤黑色素瘤患者,1:1随机分配至CLND组或观察组。
  • 共筛查5547例患者,识别1256例前哨淋巴结转移者,最终纳入483例(39%),观察组241例,CLND组242例。
  • 主要终点为无远处转移生存(DMFS),次要终点包括无复发生存(RFS)、总生存(OS)和区域淋巴结复发,按意向治疗分析。

主要发现

  • 最终分析中位随访72个月(四分位距67-77个月)。
  • 5年RFS和OS亦无差异(HR分别为1.01和0.99)。
  • CLND组3-4级不良事件32例(13%),最常见为淋巴水肿(n=20)和伤口延迟愈合(n=5),未报告严重不良事件。

临床怎么用

  • 对于前哨淋巴结阳性的皮肤黑色素瘤患者,不应常规推荐立即行完成淋巴结清扫。
  • CLND组13%的3-4级不良事件(主要为淋巴水肿)提示需权衡手术并发症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We have previously reported on the 3-year results of the phase III German Dermatologic Cooperative Oncology Group trial (DeCOG; ClinicalTrials.gov identifier: NCT02434107) comparing distant metastasis-free survival (DMFS), recurrence-free survival (RFS), and overall survival (OS) in patients with positive sentinel lymph-node biopsy who were randomly assigned to complete lymph node dissection (CLND) or observation. Here, we report the final analysis with 72 months of median follow up. PATIENTS AND METHODS: The multicenter randomized phase III trial included patients with cutaneous melanoma of the trunk and extremities who were randomly assigned (1:1) to undergo CLND or observation. DMFS was analyzed as the primary end point, and RFS, OS, and recurrences in the regional lymph node basin were secondary end points. The analysis was by intention to treat. Disease and survival information were collected quarterly. RESULTS: From January 2006 to December 2014, 5,547 patients were screened to identify 1,256 with metastases in the sentinel lymph node (SLN). Of these, 483 (39%) were included: 241 in the observation arm and 242 in the CLND arm. In the final analysis, median follow up was 72 months (interquartile range, 67-77 months). No significant treatment-related difference was seen in the 5-year DMFS between the observation and CLND arms (67.6% v 64.9%, respectively; hazard ratio [HR], 1.08; P = .87). The 5-year RFS and OS also showed no difference (HR, 1.01 and 0.99, respectively). Grade 3 and 4 adverse effects occurred in 32 patients (13%) in the CLND arm; lymphedema (n = 20) and delayed wound healing (n = 5) were most common and no serious adverse events were reported. CONCLUSION: The final results of the German Dermatologic Cooperative Oncology Group trial with a median follow up of 72 months showed higher event rates, but similar HRs compared with those at the 3-year analysis. These results confirm that immediate CLND in SLN-positive patients is not superior to observation in terms of DMFS, RFS, or OS and support not recommending CLND in patients with SLN metastasis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Leiter U, Stadler R, Mauch C, et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. J Clin Oncol. 2019. PMID: 31557067. doi:10.1200/JCO.18.02306

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。